Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

76.93EUR
11:35am EDT
Price Change (% chg)

€-0.06 (-0.08%)
Prev Close
€76.99
Open
€76.71
Day's High
€77.48
Day's Low
€76.69
Volume
1,459,245
Avg. Vol
2,300,076
52-wk High
€80.84
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.54
Market Cap (Mil.): €101,828.10
Shares Outstanding (Mil.): 1,322.62
Dividend: 2.80
Yield (%): 3.64

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.19 35.48 35.85
EPS (TTM): 2.83 -- --
ROI: -- 18.97 18.25
ROE: -- 19.75 19.12
Search Stocks

Sanofi held talks with Abbott, Mylan about mature drugs: document

PARIS - Sanofi has held talks with Abbott Laboratories , Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

UPDATE 1-Sanofi held talks with Abbott, Mylan about mature drugs -document

* Portfolio has sales of 2.1 bln eur, enterprise value 6.3 bln eur

16 Jul 2014

Sanofi held talks with Abbott, Mylan on mature drugs -document

PARIS, July 16 - Sanofi has held talks with Abbott Laboratories, Mylan and private equity firms over the possible sale of a 6.3 billion euro ($8.5 billion) portfolio of mature drugs, according to an internal document seen by Reuters.

16 Jul 2014

UPDATE 1-India caps price of 108 more medicines; drugmakers to take hit

* Move aimed towards making drugs more affordable in India

14 Jul 2014

India caps prices of 108 more medicines; drugmakers to take hit

MUMBAI, July 14 - India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.

14 Jul 2014

Sanofi dengue vaccine promising but questions remain

PARIS - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease. | Video

11 Jul 2014

RPT-Sanofi dengue vaccine promising but questions remain

(Repeats with no change to text to reach more subscribers)

11 Jul 2014

Sanofi dengue vaccine promising but questions remain

PARIS - The first vaccine against dengue fever, from France's Sanofi, provided moderate protection in a large clinical study, but questions remain as to how well it can help fight the world's fastest-growing tropical disease.

10 Jul 2014

Sanofi dengue vaccine promising but questions remain

* Currently no vaccine for expanding mosquito-borne disease

10 Jul 2014

Regeneron drug tames eczema in study

PARIS/NEW YORK - An experimental drug from Sanofi and Regeneron Pharmaceuticals Inc significantly reduced skin lesions and itching in adult patients with atopic dermatitis, a chronic form of eczema that is poorly controlled by standard drugs, the companies said on Wednesday.

09 Jul 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Plunkett Research, Ltd.
$99.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks